Zobrazeno 1 - 10
of 675
pro vyhledávání: '"nAMD"'
Autor:
Rana PJ, Deshmukh H, Shah U, Kumar V, Kanungo S, Singhal D, Mahapatra SK, Vakharia I, Jaiswal M, Gondane A, Vaidya P, Shahavi V, Shandilya H, Pawar D, Sharma A
Publikováno v:
Clinical Ophthalmology, Vol Volume 18, Pp 3071-3081 (2024)
Parth J Rana,1 Himanshu Deshmukh,2 Urmil Shah,3 Vinod Kumar,4 Sanghamitra Kanungo,5 Deepika Singhal,6 Santosh Kumar Mahapatra,7 Ira Vakharia,8 Mukesh Jaiswal,9 Ajitkumar Gondane,10 Pooja Vaidya,10 Vinayaka Shahavi,9 Harish Shandilya,11 Dattatray Pawa
Externí odkaz:
https://doaj.org/article/20e84bf7f578471db2444cb98bf346c1
Publikováno v:
Clinical Ophthalmology, Vol Volume 18, Pp 2821-2829 (2024)
Danielle Modeste,1 Christopher Stewart,2 Hajani Premanandhan,2 Mahmoud Husseiny Awad,1 Gwyn Samuel Williams1 1Ophthalmology, Singleton Hospital, Swansea Bay University Health Board, Swansea, Wales, UK; 2Swansea Bay University, Medical School, Swansea
Externí odkaz:
https://doaj.org/article/ade513d6040748df8bb55d8b9ca7b2d5
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 10, Pp 2679-2695 (2024)
Abstract Introduction The purpose of this study is to identify the factors affecting neovascular age-related macular degeneration (nAMD) disease stability after brolucizumab treatment. Methods We retrospectively analyzed the medical records of 31 pat
Externí odkaz:
https://doaj.org/article/8dbfd47ed35d443a801d3f8f8252c2d9
Autor:
Carlotta Galeone, Federica Turati, Massimo Nicolò, Mariacristina Parravano, Stela Vujosevic, Laura Bianchino, Emilia Sicari, Paolo Lanzetta
Publikováno v:
Drug Target Insights, Vol 18, Iss 1 (2024)
Objectives: To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept,
Externí odkaz:
https://doaj.org/article/bac9043191bf4936a31678d0e5c3b7ce
Autor:
Ian M. Leitch, Michael Gerometta, David Eichenbaum, Robert P. Finger, Nathan C. Steinle, Megan E. Baldwin
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 7, Pp 1857-1875 (2024)
Abstract The development of treatments targeting the vascular endothelial growth factor (VEGF) signaling pathways have traditionally been firstly investigated in oncology and then advanced into retinal disease indications. Members of the VEGF family
Externí odkaz:
https://doaj.org/article/d12fa22b9c0e429b8a9d7b36d70b8f8f
Autor:
Maximino J. Abraldes, Pilar Calvo, María Gámez Lechuga, María Merino, Teresa Martín Lorenzo, Paulina Maravilla-Herrera, Beatriz Gil Jiménez, José M. Ruiz-Moreno
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 7, Pp 1925-1935 (2024)
Abstract Introduction Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients’ and their famil
Externí odkaz:
https://doaj.org/article/df76b88a0b1f43f8889134bdda59001a
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 6, Pp 1407-1416 (2024)
Abstract The pending introduction of home-based optical coherence tomography (OCT) in managing neovascular age-related macular degeneration (nAMD) has sparked interesting debates. Advocates assert that home-based OCT will revolutionize care of patien
Externí odkaz:
https://doaj.org/article/985562f3a7ec4fa8bce407a7ddc4e4e4
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveThe study aims to investigate the protective effect of Mingjing granule (MG) in a fibrovascular membrane rat model of neovascular age-related macular degeneration (nAMD) and explore the underlying mechanism.MethodsThe nAMD fibrovascular memb
Externí odkaz:
https://doaj.org/article/9e9b85959f5b487780bfdebcdf47b496
Publikováno v:
Российский офтальмологический журнал, Vol 16, Iss 4, Pp 7-26 (2023)
Purpose: data analysis of Russia’s first register of neovascular age-related macular degeneration (nAMD) — a web-based system for clinical monitoring of nAMD patients designed to collect and accumulate the data on such patients, their demographic
Externí odkaz:
https://doaj.org/article/294ffaa941424e60ab3fed19947e46e3
Publikováno v:
Pharmaceuticals, Vol 17, Iss 8, p 1000 (2024)
Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label us
Externí odkaz:
https://doaj.org/article/59bbc51949af477da89edf28e0b430e1